Sperm allocation pattern during a reproductive season in the copulating marine cottoid species, Alcichthys alcicornis

H. Munehara,Hiroshi Murahana

DOI: https://doi.org/10.1007/s10641-010-9644-7

2010-04-21

Environmental Biology of Fishes

Abstract:

What problem does this paper attempt to address?

Sarcocystis Meningoencephalitis in a Northern Gannet (Morus bassanus)

M. Spalding,C. Yowell,D. Lindsay,E. Greiner,J. Dame

DOI: https://doi.org/10.7589/0090-3558-38.2.432

2002-04-01

Journal of Wildlife Diseases

Abstract:Sarcocystis sp. schizonts were found in the cerebellum of a northern gannet (Morus bassanus), exhibiting neurologic signs, found on the Florida (USA) east coast. Based upon molecular characterization of DNA isolated from the brain of the gannet, this Sarcocystis sp. appeared to be closely related, if not identical, to an unnamed Sarcocystis sp. typified by isolates 1085 and 1086 collected from feces of a Virginia opossum (Didelphis virginiana) on the east coast of Florida. Because the life cycle of this parasite appears to be land based, urban waste discharge to marine/estuarine environments may be a source of infection for marine species.
A claims‐based, machine‐learning algorithm to identify patients with pulmonary arterial hypertension

Bethany Hyde,Carly J. Paoli,Sumeet Panjabi,Katherine C. Bettencourt,Karimah S. Bell Lynum,Mona Selej

DOI: https://doi.org/10.1002/pul2.12237

2023-06-07

Pulmonary Circulation

Abstract:Many patients with pulmonary arterial hypertension (PAH) experience substantial delays in diagnosis, which is associated with worse outcomes and higher costs. Tools for diagnosing PAH sooner may lead to earlier treatment, which may delay disease progression and adverse outcomes including hospitalization and death. We developed a machine‐learning (ML) algorithm to identify patients at risk for PAH earlier in their symptom journey and distinguish them from patients with similar early symptoms not at risk for developing PAH. Our supervised ML model analyzed retrospective, de‐identified data from the US‐based Optum® Clinformatics® Data Mart claims database (January 2015 to December 2019). Propensity score matched PAH and non‐PAH (control) cohorts were established based on observed differences. Random forest models were used to classify patients as PAH or non‐PAH at diagnosis and at 6 months prediagnosis. The PAH and non‐PAH cohorts included 1339 and 4222 patients, respectively. At 6 months prediagnosis, the model performed well in distinguishing PAH and non‐PAH patients, with area under the curve of the receiver operating characteristic of 0.84, recall (sensitivity) of 0.73, and precision of 0.50. Key features distinguishing PAH from non‐PAH cohorts were a longer time between first symptom and the prediagnosis model date (i.e., 6 months before diagnosis); more diagnostic and prescription claims, circulatory claims, and imaging procedures, leading to higher overall healthcare resource utilization; and more hospitalizations. Our model distinguishes between patients with and without PAH at 6 months before diagnosis and illustrates the feasibility of using routine claims data to identify patients at a population level who might benefit from PAH‐specific screening and/or earlier specialist referral.

cardiac & cardiovascular systems,respiratory system
Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension

Athénaïs Boucly,Antoine Beurnier,Ségolène Turquier,Mitja Jevnikar,Pascal de Groote,Ari Chaouat,Céline Cheron,Xavier Jaïs,François Picard,Grégoire Prévot,Anne Roche,Sabina Solinas,Vincent Cottin,Fabrice Bauer,David Montani,Marc Humbert,Laurent Savale,Olivier Sitbon,

DOI: https://doi.org/10.1183/13993003.00197-2024

IF: 24.3

2024-04-25

European Respiratory Journal

Abstract:Background and Aims Haemodynamic variables are prognostic factors in pulmonary arterial hypertension (PAH). However, right heart catheterization (RHC) is not systematically recommended to assess the risk-status during follow-up. This study aimed to assess the added value of haemodynamic variables in prevalent patients to predict the risk of death or lung transplantation according to their risk status assessed by the non-invasive 4 strata model as recommended by the European guidelines. Methods We evaluated incident patients with PAH enrolled in the French PAH Registry between 2009 and 2020 who had a first follow-up RHC. Cox regression identified, in each follow-up risk status, haemodynamic variables significantly associated with transplant-free survival (TFS). Optimal thresholds were determined by time-dependent Receiver-Operating Characteristics. Several multivariable Cox regression models were performed to identify the haemodynamic variables improving the non-invasive risk stratification model. Results We analysed 1240 incident patients reassessed within a year by RHC. None of haemodynamic variable were significantly associated with TFS among low-risk (n=386) or high-risk (n=71) patients. Among patients at intermediate (-low, n=483, -high, n=300) risk at first follow-up, multivariable models including either stroke volume index (SVi) or mixed venous oxygen saturation (SvO 2 ) were the best. The prognostic performance of refined 6 strata risk stratification model including the non-invasive 4 strata model and SVi>37 mL·m −2 and/or SvO 2 >65% for patients at intermediate-risk (Area Under the Curve 0.81, c-index 0.74), was better than that of 4 strata model (0.79, p=0.009; c-index 0.72). Conclusions Cardiopulmonary haemodynamics may improve risk stratification at follow-up in patients at intermediate-risk.

respiratory system
Improved Risk Prediction Using a Refined European Guidelines Instrument in Pulmonary Arterial Hypertension Related to Congenital Heart Disease

Alexandra C van Dissel,Michele D'Alto,Andrea Farro,Harold Mathijssen,Marco C Post,Pier P Bassareo,Arie P J van Dijk,Barbara J M Mulder,Berto J Bouma

DOI: https://doi.org/10.1016/j.amjcard.2024.08.027

2024-09-02

Abstract:European guidelines advocate a goal-oriented treatment approach in pulmonary arterial hypertension (PAH), based on a comprehensive risk assessment instrument, which has been validated in several PAH subgroups. We investigated its discriminatory ability, and explored tricuspid annular plane systolic excursion (TAPSE) and revised thresholds to improve its predictability within the adult congenital heart disease (CHD) population. In total, 223 adults (42±16 years, 66% female, 68% Eisenmenger) were enrolled from five European PAH-CHD expert centers. Patients were classified as 'Low', 'Intermediate', or 'High' risk at baseline visit and at follow-up within 4-18 months. By the general PAH guidelines instrument, survival did not differ between the risk groups (P=n.s.), mostly due to skewed group distribution. Reclassifying patients using revised thresholds for N-terminal pro-brain natriuretic peptide (NT-proBNP) and 6-minute walk distance (6MWD) (i.e., 'Low', 'Intermediate', 'High' as <500, 500-1400, >1400 ng/l and >400, 165-400 and <165 m, respectively) and use of TAPSE ('Low', 'Intermediate', 'High' as >20, 16-20 and <16mm) significantly improved discrimination between the risk groups both at baseline and follow-up (P=0.001, ROC increase from 0.648 to 0.701), reclassifying 64 (29%) patients. Irrespective of follow-up risk group, survival was better for patients with higher proportions of low-risk variables. Improvement to a 'Low-risk' profile at a median of 9 months follow-up provided improved survival comparable to survival of patients who remained in the 'Low risk' group. In conclusion, the external validity of general risk instrument for PAH appeared to be of limited discriminatory value in PAH-CHD patients. We propose a refined risk instrument with improved discrimination for PAH-CHD.
Risk stratification and medical therapy of pulmonary arterial hypertension

Nazzareno Galiè,Richard N. Channick,Robert P. Frantz,Ekkehard Grünig,Zhi Cheng Jing,Olga Moiseeva,Ioana R. Preston,Tomas Pulido,Zeenat Safdar,Yuichi Tamura,Vallerie V. McLaughlin

DOI: https://doi.org/10.1183/13993003.01889-2018

IF: 24.3

2019-01-01

European Respiratory Journal

Abstract:Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.

respiratory system
A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines

Fabio Dardi,Alessandra Manes,Daniele Guarino,Elisa Zuffa,Alessandro De Lorenzis,Ilenia Magnani,Mariangela Rotunno,Alberto Ballerini,Gerardo Vito Lo Russo,Elena Nardi,Nazzareno Galiè,Massimiliano Palazzini

DOI: https://doi.org/10.1136/openhrt-2021-001725

Open Heart

Abstract:Objective: To optimise treatment of patients with pulmonary arterial hypertension (PAH), the 2015 European Society of Cardiology/European Respiratory Society guidelines recommend using risk stratification, with the aim of patients achieving low-risk status. Previous analyses of registries made progress in using risk stratification approaches, however, the focus is often on patients with a low-risk prognosis, whereas most PAH patients are in intermediate-risk or high-risk categories. Using only six parameters with high prognostic relevance, we aimed to demonstrate a pragmatic approach to individual patient risk assessment to discriminate between patients at low risk, intermediate risk and high risk of death. Methods: Risk assessment was performed combining six parameters in four criteria: (1) WHO functional class, (2) 6 min walk distance, (3) N-terminal pro-brain natriuretic peptide (BNP)/BNP plasma levels or right atrial pressure and (4) cardiac index or mixed venous oxygen saturation. Assessments were made at baseline and at first follow-up after 3-4 months. Results: 725 PAH treatment-naive patients were analysed. Survival estimates between risk groups were statistically significant at baseline and first follow-up (p<0.001), even when the analysis was performed within PAH etiological subgroups. Similar results were observed in 208 previously treated PAH patients. Furthermore, patients who remained at or improved to low risk had a significantly better estimated survival compared with patients who remained at or worsened to intermediate risk or high risk (p≤0.005). Conclusion: The simplified risk-assessment method can discriminate idiopathic, connective-tissue-disease-associated and congenital-heart-disease-associated PAH patients into meaningful high-risk, intermediate-risk and low-risk groups at baseline and first follow-up. This pragmatic approach reinforces targeting a low-risk profile for PAH patients.
Abstract 15889: An Artificial Intelligence-Derived Pediatric Pulmonary Hypertension Risk Prediction Model From the Pediatric Pulmonary Hypertension Network (PPHNet) Registry

Megan Griffiths,Cedric Manlhiot,Bhargava K Chinni,Lynn A Sleeper,Steven Abman,Erika Rosenzweig,Lewis H Romer,Mary P Mullen,Shili Lin,raymond Benza,Allen D Everett,PPHNet Investigators,

DOI: https://doi.org/10.1161/circ.148.suppl_1.15889

IF: 37.8

2023-11-07

Circulation

Abstract:Introduction: Risk prediction is fundamental to guiding pulmonary hypertension (PH) treatment and is a key part of PH guideline based care. Data-driven risk prediction in pediatric PH has been lacking, relying instead on expert opinion. Objective: Use the multi-center Pediatric Pulmonary Hypertension Network (PPHNet) registry to develop a pediatric PH risk model. Methods: Pediatric PH patients (WSPH 1/3) enrolled in the PPHNet were used in this study and randomly split into train (80%) and test cohorts (20%). 176 variables were suitable for analysis including demographics, imaging, hemodynamics, functional/exercise testing, laboratory values, symptoms, and comorbidities. Boruta feature selection with random forest classifier identified variables that predicted the composite outcome of time to death, transplant or reverse Potts shunt. 2 The prediction model was built using an extreme gradient boost classifier with parameter tuning using Bayesian optimization. Model performance was quantified using confusion matrices, calculated sensitivity, specificity, AUC-ROC, and calibration slope. Results: A total of 1232 patients (985 Train, 247 test) were appropriate for inclusion; 134 patients (10.9%) met the composite outcome) with follow-up to 4 years from diagnosis. 37 variables were isolated for the prediction model. The Model performed strongly in the test cohort with an AUROC of 87% (Figure 1A), sensitivity of 85%, and specificity of 77%. Predicted probabilities were stratified into 3 major risk groups based on 1-year risk of event (Figure 1B; low 15%) with good agreement between predicted and observed outcomes. Conclusions: Using the multicenter PPHNet cohort, we developed a well calibrated 1-year risk prediction model for pediatric groups 1 and 3 PH. This model is uniquely trained on incident and prevalent pediatric patients and could enable accurate identification of high-risk patients in need of aggressive therapy.

cardiac & cardiovascular systems,peripheral vascular disease
Identifying consistent echocardiographic thresholds for risk stratification in pulmonary arterial hypertension

Bettia E. Celestin,Shadi P. Bagherzadeh,Kenzo Ichimura,Everton J. Santana,Pablo Amador Sanchez,Tobore Tobore,Anna R. Hemnes,Anton Vonk Noordegraaf,Michael Salerno,Roham T. Zamanian,Andrew J. Sweatt,Francois Haddad

DOI: https://doi.org/10.1002/pul2.12361

2024-05-25

Pulmonary Circulation

Abstract:Several indices of right heart remodeling and function have been associated with survival in pulmonary arterial hypertension (PAH). Outcome analysis and physiological relationships between variables may help develop a consistent grading system. Patients with Group 1 PAH followed at Stanford Hospital who underwent right heart catheterization and echocardiography within 2 weeks were considered for inclusion. Echocardiographic variables included tricuspid annular plane systolic excursion (TAPSE), right ventricular (RV) fractional area change (RVFAC), free wall strain (RVFWS), RV dimensions, and right atrial volumes. The main outcome consisted of death or lung transplantation at 5 years. Mathematical relationships between variables were determined using weighted linear regression and severity thresholds for were calibrated to a 20% 1‐year mortality risk. PAH patients (n = 223) had mean (SD) age of 48.1 (14.1) years, most were female (78%), with a mean pulmonary arterial pressure of 51.6 (13.8) mmHg and pulmonary vascular resistance index of 22.5(6.3) WU/m2. Measures of right heart size and function were strongly related to each other particularly RVFWS and RVFAC (R2 = 0.82, p

cardiac & cardiovascular systems,respiratory system
Precision phenotyping from routine laboratory parameters for machine learning out-of-hospital survival prediction using 4D time-dependent SHAP plots in an all-comers prospective PCI registry

Paul-Adrian Calburean,Anda-Cristina Scurtu,Paul Grebenisan,Ioana-Andreea Nistor,Victor Vacariu,Reka-Katalin Drincal,Ioana Paula Sulea,Petru Mesaros,Tiberiu Oltean,Laszlo Hadadi

DOI: https://doi.org/10.1101/2024.08.31.24312888

2024-09-03

Abstract:Introduction Out-of-hospital mortality in coronary artery disease (CAD) is particularly high and established adverse event prediction tools are yet to be available. Our study aimed to investigate whether precision phenotyping can be performed using routine laboratory parameters for the prediction of out-of-hospital survival in a CAD population treated by percutaneous coronary intervention (PCI). Materials and methods All patients treated by PCI and discharged alive in a tertiary center between January 2016 - December 2022 that have been included prospectively in the local registry were analyzed. 115 parameters from the PCI registry and 266 parameters derived from routine laboratory testing were used. An extreme gradient-boosted decision tree machine learning (ML) algorithm was trained and used to predict all-cause and cardiovascular-cause survival. Results A total of 7186 PCI hospitalizations for 5797 patients were included with more than 610.000 laboratory values. All-cause and cardiovascular cause mortality was 17.5% and 12.2%, respectively, during a median follow-up time of 1454 (687 - 2072) days. The integrated area under the receiver operator characteristic curve for prediction of all-cause and cardiovascular cause mortality by the ML on the validation dataset was 0.844 and 0.837, respectively (all p<0.001). The integrated area under the precision-recall curve for prediction of all-cause and cardiovascular cause mortality by the ML on the validation dataset was 0.647 and 0.589, respectively (all p<0.001). Conclusion Precise survival prediction in CAD can be achieved using routine laboratory parameters. ML outperformed clinical risk scores in predicting out-of-hospital mortality in a prospective all-comers PCI population.
Identification of metabolic biomarkers in idiopathic pulmonary arterial hypertension using targeted metabolomics and bioinformatics analysis

Chuang Yang,Yi-Hang Liu,Hai-Kuo Zheng

DOI: https://doi.org/10.1038/s41598-024-76514-7

IF: 4.6

2024-10-27

Scientific Reports

Abstract:Pulmonary arterial hypertension (PAH) is a life-threatening disease with a poor prognosis, and metabolic abnormalities play a critical role in its development. This study used metabolomics, machine learning algorithms and bioinformatics to screen for potential metabolic biomarkers associated with the diagnosis of PAH. In this study, plasma samples were collected from 17 patients diagnosed with idiopathic pulmonary arterial hypertension (IPAH) and 20 healthy controls. Plasma metabolomic profiling was performed by high-performance liquid chromatography-mass spectrometry. Gene profiles of PAH patients were obtained from the GEO database. Key differentially expressed metabolites (DEMs) and metabolism-related genes were subsequently identified using machine learning algorithms. Twenty differential plasma metabolites associated with IPAH were identified (VIP score > 1 and p < 0 0.05), and enrichment analysis revealed the arginine biosynthesis pathway as the most altered pathway. Using machine learning models, including least absolute shrinkage and selection operator (LASSO), random forest (RF) and support vector machine (SVM), we extracted key metabolites that correlated with clinical phenotypes. Our results suggested that five metabolites, kynurenine, homoserine, tryptophan, AMP, and spermine, are potential biomarkers for IPAH. Bioinformatics analysis also identified 3 metabolism-related genes, MAPK6, SLC7A11 and CDC42BPA, that are strongly correlated with pulmonary hypertension, demonstrating strong predictive power and clinical relevance. Our findings revealed some key genes associated with metabolism in PH, and provided crucial information about complex metabolic reprogramming signals and may lead to the identification of useful metabolic biomarkers for the diagnosis of PAH.

multidisciplinary sciences
Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment

Clara Hjalmarsson,Barbro Kjellström,Kjell Jansson,Magnus Nisell,David Kylhammar,Mohammad Kavianipour,Göran Rådegran,Stefan Söderberg,Gerhard Wikström,Dirk M. Wuttge,Roger Hesselstrand

DOI: https://doi.org/10.1183/23120541.00854-2020

IF: 4.239

2021-04-22

ERJ Open Research

Abstract:Despite systematic screening and improved treatment strategies, the prognosis remains worse in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) compared to patients with idiopathic/hereditary pulmonary arterial hypertension (IPAH). We aimed to investigate differences in clinical characteristics, outcome, and performance of the ESC/ERS risk stratification tool in these patient groups. This retrospective analysis included incident patients with CTD-PAH (n=197, of which 64 had interstitial lung disease, ILD) or IPAH (n=305) enrolled in the Swedish PAH Register 2008–2019. Patients were classified as low, intermediate, or high risk at baseline, according to the “SPAHR-equation”. 1-year survival, stratified by type of PAH, was investigated by Cox proportional regression. At baseline, CTD-PAH patients had lower diffusing capacity for carbon monoxide and lower haemoglobin, but, at the same time, lower N-terminal prohormone-brain natriuretic peptide, longer 6 min walking distance, better hemodynamics, and more often a low-risk profile. No difference in age, WHO-FC, or renal function between groups was found. 1-year survival rates were 75, 82 and 83%, in patients with CTD-PAH with ILD, CTD-PAH without ILD, and IPAH, respectively. The 1-year mortality rates for low-, intermediate-, and high-risk groups in the whole cohort were 0, 18 and 34% (p<0.001), respectively. Corresponding percentages for CTD-PAH with ILD, CTD-PAH without ILD, and IPAH patients were: 0, 26, 67% (p=0.008); 0, 19, 39% (p=0.004); and 0, 16, 29% (p=0.001), respectively. The ESC/ERS risk assessment tool accurately identified low-risk patients but underestimated the 1-year mortality rate of CTD-PAH and IPAH patients assessed as having intermediate risk at diagnosis.
Impact of left heart disease risk factors on risk stratification and treatment response in pulmonary arterial hypertension

K Kearney,J Anderson,R Cordina,M Lavender,D Celermajer,N Collins,N Dwyer,D Keating,T Williams,H Whitford,K Whyte,R Weintraub,A Keogh,E Kotlyar,E M T Lau

DOI: https://doi.org/10.1093/eurheartj/ehab724.1958

IF: 39.3

2021-10-01

European Heart Journal

Abstract:Abstract Background Contemporary registries have documented a change in the epidemiology of PAH patients displaying increasing co-morbidities associated with left heart disease (LHD). These patients are often excluded from randomized clinical trials. It is unclear whether the presence of LHD comorbidities may adversely impact the accuracy of risk stratification and response to PAH therapy. Method Data was extracted from the Pulmonary Hypertension Society of Australia and New Zealand registry for incident patients with a diagnosis with idiopathic/heritable/toxin-induced (I/H/D)-PAH and connective tissue disease (CTD) associated PAH from 2011 - 2020. Patients without available medication and follow up data were excluded. We used the AMBITION trial exclusion criteria to define the subpopulation with LHD risk factors and haemodynamic phenotype (PAH-rLHD). Results 489 patients (I/H/D-PAH=251, CTD-PAH=238) were included in our analysis, with 103 (21.0%) fulfilling the definition of PAH-rLHD (34 had ≥3 risk factors for left heart disease (rLHD-hypertension, diabetes, obesity or ischaemic heart disease) and 76 had borderline haemodynamics (mean capillary wedge pressure 13–15 with pulmonary vascular resistance <500 dynes sec/cm5) including 7 who met both criteria). Compared to classical PAH, patients with PAH-rLHD were older at diagnosis (66±13 vs 58±19, p<0.001), had lower pulmonary vascular resistance (PVR: 393±266 vs 708±391, p=0.031) but worse exercise capacity (6MWD: 286±130m vs 327±136m, p=0.005). PAH-rLHD were more likely to be started on initial monotherapy, compared with “classical” PAH (73% vs 56%, p=0.002). In the monotherapy groups, endothelin receptor antagonists (ERA) were used in 73% PAH-rLHD, compared with 66% in classical PAH group. Both groups exhibited similar response to both mono- and combination therapy with commensurate improvements in WHO functional class (mean change 0.3±0.6 vs 0.3±0.8, p=0.443) and 6-minute walk distance (mean change 44±82 vs 48±101, p=0.723). There was no difference in survival between classical PAH and PAH-rLHD (log rank, p=0.29). The REVEAL 2.0 risk score effectively discriminated risk in both populations at baseline and first follow up (classical PAH: baseline C statistic 0.750, follow up 0.774 and PAH-rLHD: baseline C statistic 0.756, follow up 0.791). Conclusion Despite lower PVR at diagnosis, PAH-rLHD patients and “classical” PAH demonstrate similar response to first-line therapy with similar long term survival. The REVEAL 2.0 risk score can be effectively applied to the subpopulation of PAH-rLHD in real life clinical practice. Funding Acknowledgement Type of funding sources: None.

cardiac & cardiovascular systems
Risk Assessment in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: CSTAR-PAH Cohort Study.

Qian Wang,Junyan Qian,Mengtao Li,Xiao Zhang,Wei,Xiaoxia Zuo,Ping Zhu,Shuang Ye,Wei Zhang,Yi Zheng,Wufang Qi,Yang Li,Zhuoli Zhang,Feng Ding,Jieruo Gu,Yi Liu,Can Huang,Jiuliang Zhao,Yongtai Liu,Zhuang Tian,Yanhong Wang,Miaojia Zhang,Xiaofeng Zeng

DOI: https://doi.org/10.1177/20406223221112528

2022-01-01

Therapeutic Advances in Chronic Disease

Abstract:Objective: This study evaluated the prognostic value of the multivariable risk assessment for systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH). Methods: A multicenter prospective cohort of SLE-associated PAH (CSTAR-PAH cohort) diagnosed based on right heart catheterization (RHC) was established. Baseline and follow-up records were collected. Three methods of risk assessment, including (1) the number of low-risk criteria, based on World Health Organization functional class (WHO FC), 6-min walking distance (6MWD), right atrial pressure (RAP), and cardiac index (CI); (2) the three-strata stratification based on the average risk score of four variables (WHO FC, 6MWD, RAP, and CI); and (3) the four-strata stratification based on COMPARE 2.0 model were applied. A risk-assessment method using three noninvasive low-risk criteria was applied at the first follow-up visit. Survival curves between patients with different risk groups were compared by Kaplan-Meier's estimation and log-rank test. Results: Three-hundred and ten patients were enrolled from 14 PAH centers. All methods of stratification at baseline and first follow-up significantly discriminated long-term survival. Survival rates were also significantly different based on the noninvasive risk assessment in first follow-up visit. Survival deteriorated with the escalation of risk from baseline to first follow-up. Patients with baseline serositis had a higher rate of risk improvement in their follow-up. Conclusion: The risk assessment has a significant prognostic value at both the baseline and first follow-up assessment of SLE-associated PAH. A noninvasive risk assessment can also be useful when RHC is not available during follow-up. Baseline serositis may be a predictor of good treatment response in patients with SLE-associated PAH.
Cerebral Phaeohyphomycosis in Two Dogs and a Cat

D. Dillehay,J. Ribas,J. Newton,R. Kwapien

DOI: https://doi.org/10.1177/030098588702400217

1987-03-01

Abstract:1 Appelby EC: Tumours of the adrenal gland and paraganglia. Bull WHO 53:227-235, 1976 2 Brewer BD: Disorders of equine calcium metabolism. Compend Contin Educ Pract Vet 4:244-25 1, 1982 3 Capen CC: Tumors of the endocrine glands. In: Tumors in Domestic Animals, ed. Moulton JE, 2nd ed., pp. 385392. University of California Press, Berkeley, 1978 4 Capen CC: The endocrine glands. In: Pathology of Domestic Animals, ed. Jubb KVF, Kennedy PC, and Palmer N, 3rd ed., pp. 237-303. Academic Press, Orlando, 1985 5 Esplin DG, Taylor J L Hypercalcemia in a horse with lymphosarcoma. J Am Vet Med Assoc 170: 180-1 82,1977 6 Evans LH, Hubben K, Siegel ET: Clinico-pathologic conference. J Am Vet Med Assoc 152:1778-1786, 1968 7 Kelly DF, Siegel ET, Berg P: The adrenal gland in dogs with hyperadrenocorticalism. Vet Path01 8:385400, 197 1 8 Meuten DJ, Price SM, Seiler RM, Krook L Gastric carcinoma with pseudohyperparathyroidism in a horse. Cornell Vet 68:179-195, 1978 9 Raker C W, Fegley H: Clinico-pathologic conference. J Am Vet Med Assoc 147:848-860, 1965 10 Silva EG, Mackay B, Samaan NA, Hickey RC: Adrenocortical carcinomas: an ultrastructural study of 22 cases. Ultrastruct Pathol3: 1-7, 1982
Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype

Matteo Toma,Giulio Savonitto,Carlo Maria Lombardi,Edoardo Airò,Mauro Driussi,Piero Gentile,Luke Howard,Martina Moschella,Emma Di Poi,Matteo Pagnesi,Simonetta Monti,Valentino Collini,Luciana D'Angelo,Veronica Vecchiato,Alberto Giannoni,Marianna Adamo,Davide Barbisan,Carolina Bauleo,Andrea Garascia,Marco Metra,Gianfranco Sinagra,Francesco Lo Giudice,Davide Stolfo,Pietro Ameri

DOI: https://doi.org/10.1007/s00392-024-02448-9

2024-04-15

Abstract:Aim: To obtain real-world evidence about the features and risk stratification of pulmonary arterial hypertension (PAH) with a left heart disease (LHD) phenotype (PAH-LHD). Methods and results: By reviewing the records of consecutive incident PAH patients at 7 tertiary centers from 2001 to 2021, we selected 286 subjects with all parameters needed to determine risk of death at baseline and at first follow-up with COMPERA and COMPERA 2.0 scores. Fifty seven (20%) had PAH-LHD according to the AMBITION definition. Compared with no-LHD ones, they were older, had higher BMI, more cardiovascular comorbidities, higher E/e' ratio and left atrial area, but lower BNP concentrations and better right ventricular function and pulmonary hemodynamics. Survival was comparable between PAH-LHD and no-LHD patients, although the former were less commonly treated with dual PAH therapy. Both COMPERA and COMPERA 2.0 discriminated all-cause mortality risk of PAH-LHD at follow-up, but not at baseline. Risk profile significantly improved during follow-up only when assessed by COMPERA 2.0. At multivariable analysis with low-risk status as reference, intermediate-high and high-risk, but not LHD phenotype, were associated with higher hazard of all-cause mortality. Results were comparable in secondary analyses including patients in the last 10 years and atrial fibrillation and echocardiographic abnormalities as additional criteria for PAH-LHD. Conclusions: In real life, PAH-LHD patients are frequent, have less severe disease and are less likely treated with PAH drug combinations than no-LHD. The COMPERA 2.0 model may be more appropriate to evaluate their mortality risk during follow-up and how it is modulated by therapy.
Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics

Ruilin Quan,Shian Huang,Lingpin Pang,Jieyan Shen,Weifeng Wu,Fangming Tang,Xiulong Zhu,Weiqing Su,Jingzhi Sun,Zaixin Yu,Lemin Wang,Xianyang Zhu,Changming Xiong,Jianguo He

DOI: https://doi.org/10.1186/s12872-022-02492-1

IF: 2.174

2022-02-16

BMC Cardiovascular Disorders

Abstract:Abstract Background There is no generally accepted comprehensive risk prediction model cooperating risk factors associated with heart failure and pulmonary hemodynamics for patients with pulmonary hypertension due to left heart disease (PH-LHD). We aimed to explore outcome correlates and evaluate incremental prognostic value of pulmonary hemodynamics for risk prediction in PH-LHD. Methods Consecutive patients with chronic heart failure undergoing right heart catheterization were prospectively enrolled. The primary endpoint was all-cause mortality. Individual variable selection was performed by machine learning methods. Cox proportional hazards models were conducted to identify the association between variables and mortality. Incremental value of hemodynamics was evaluated based on the Seattle heart failure model (SHFM) and Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) scores. Results A total of 276 PH-LHD patients were enrolled, with a median follow-up time of 34.7 months. By L1-penalized regression model and random forest approach, diastolic pressure gradient (DPG) and mixed venous oxygen saturation (SvO 2 ) were the hemodynamic predictors most strongly associated with mortality (coefficient: 0.0255 and -0.0176, respectively), with consistent significance after adjusted for SHFM [DPG: HR 1.067, 95% CI 1.024–1.113, P = 0.022; SvO 2 : HR 0.969, 95% CI 0.953–0.985, P = 0.002] or MAGGIC (DPG: HR 1.069, 95% CI 1.026–1.114, P = 0.011; SvO 2 : HR 0.970, 95% CI 0.954–0.986, P = 0.004) scores. The inclusion of DPG and SvO 2 improved risk prediction compared with using SHFM [net classification improvement (NRI): 0.468 (0.161–0.752); integrated discriminatory index (IDI): 0.092 (0.035–0.171); likelihood ratio test: P < 0.001] or MAGGIC [NRI: 0.298 (0.106–0.615); IDI: 0.084 (0.033–0.151); likelihood ratio: P < 0.001] scores alone. Conclusion In PH-LHD, pulmonary hemodynamics can provide incremental prognostic value for risk prediction. Clinical trial registration : NCT02164526 at https://clinicaltrials.gov .

cardiac & cardiovascular systems
Pathologic Quiz Case: An 11-Day-Old Boy With Lethargy, Jaundice, Fever, and Melena

N. Kelly,M. D. Raible,Aliya N. Husain

DOI: https://doi.org/10.1043/0003-9985(2000)124<0469:PQCADO>2.0.CO;2

2009-10-01

Abstract:
Precision phenotyping from routine laboratory parameters for out of hospital survival prediction in an all comers prospective PCI registry

Paul-Adrian Călburean,Marius Harpa,Anda-Cristina Scurtu,Paul Grebenișan,Ioana-Andreea Nistor,Victor Vacariu,Reka-Katalin Drincal,Ioana Paula Şulea,Tiberiu Oltean,Petru-Vasile Mesaroş,László Hadadi

DOI: https://doi.org/10.1038/s41598-024-76936-3

2024-10-22

Abstract:Out-of-hospital mortality in coronary artery disease (CAD) is particularly high and established adverse event prediction tools are yet to be available. Our study aimed to investigate whether precision phenotyping can be performed using routine laboratory parameters for the prediction of out-of-hospital survival in a CAD population treated by percutaneous coronary intervention (PCI). All patients treated by PCI and discharged alive in a tertiary center between January 2016 - December 2022 that have been included prospectively in the local registry were analyzed. 115 parameters from the PCI registry and 266 parameters derived from routine laboratory testing were used. An extreme gradient-boosted decision tree machine learning (ML) algorithm was trained and used to predict all-cause and cardiovascular-cause survival. A total of 4027 patients with 4981 PCI hospitalizations were randomly included in the 70% training dataset and 1729 patients with 2160 PCI hospitalizations were randomly included in the 30% validation dataset. All-cause and cardiovascular cause mortality was 17.5% and 12.2%. The integrated area under the receiver operator characteristic curve for prediction of all-cause and cardiovascular cause mortality by the ML on the validation dataset was 0.844 and 0.837, respectively (all p < 0.001). Parameters reflecting renal function (first and maximum serum creatinine), hematologic function (mean corpuscular hemoglobin concentration, platelet distribution width), and inflammatory status (lymphocyte per monocyte ratio) were among the most important predictors. Accurate out-of-hospital survival prediction in CAD can be achieved using routine laboratory parameters. ML outperformed clinical risk scores in predicting out-of-hospital mortality in a prospective all-comers PCI population and has the potential to precisely phenotype patients.
Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension

Wassim H Fares,Lavanya Bellumkonda,Adriano R Tonelli,Shannon S Carson,Paul M Hassoun,Terence K Trow,Erica L Herzog,Naftali Kaminski,Cyrus A Kholdani,Lixia Zhang,Yi Zhou,Jeffrey P Hammel,Raed A Dweik

DOI: https://doi.org/10.1016/j.healun.2015.12.028

Abstract:Background: Pulmonary arterial hypertension (PAH) is a progressive, fatal disease. Current prognostic models are not ideal, and identifying more accurate prognostic variables is needed. The objective of this study was to evaluate the relative prognostic value of the right atrial pressure/pulmonary artery wedge pressure (RAP/PAWP) ratio in PAH patients. We hypothesized that the RAP/PAWP ratio is more predictive of survival than any of the other measured or calculated hemodynamic variables. Methods: We performed a secondary analysis of a PAH cohort (Cohort 1) and validated our results in a separate cohort (Cohort 2). Cohort 1 included primarily patients enrolled in prospective, short-term, randomized clinical trials and subsequently followed long term. Cohort 2 included patients prospectively enrolled in a PAH registry at a tertiary PAH referral center. Results: Cohort 1 (n = 847) and Cohort 2 (n = 697) had a mean age of 47 and 54 years, respectively. Most were female (78% and 73%, respectively), Caucasian (83% and 82%), with advanced functional class disease status (New York Heart Association Functional Class III/IV 85% and 68%) and with significantly elevated hemodynamics (mean RAP/PAWP ratio: 1.2 and 1.0; pulmonary vascular resistance: 13.5 and 9.4 Wood units). RAP/PAWP ratio indicated a 1-year hazard ratio of 1.44 (p = 0.0001) and 1.35, respectively (p < 0.0001), and was the most consistently predictive hemodynamic variable across the 2 cohorts. These results remain valid even when adjusted for other covariables in multivariable regression models. Conclusions: The RAP/PAWP ratio is a more specific predictor of survival than any other hemodynamic variable, and we recommend that it be used in clinical prognostication and PAH predictive models.
Continuous long-term heart rate variability and risk assessment in pulmonary hypertension

Mads Ørbæk Andersen,Soren Zöga Diederichsen,Jesper Hastrup Svendsen,Jørn Carlsen

DOI: https://doi.org/10.1136/openhrt-2023-002302

2023-07-01

Open Heart

Abstract:Objective Current multimodal risk assessment for pulmonary hypertension (PH) has been redefined with a simplified assessment for follow-up in the new European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines. Follow-up risk assessment parameters include WHO functional class, 6 min walk test and N-terminal pro-brain natriuretic peptide. Although these parameters have prognostic implications assessment reflect data relating to specific time points. Methods Patients diagnosed with PH received an implantable loop recorder (ILR) to monitor daytime and night-time heart rate (HR), HR variability (HRV) and daily physical activity. Associations between the ILR measurements and established risk parameters were analysed using correlations, linear mixed models as well as logistical mixed models for addressing the ESC/ERS risk-score. Results 41 patients (median age: 56 years, range: 44–61.5 years) were included. Continuous monitoring had a median duration of 755 days (range: 343–1138 days), totalling 96 patient-years. In the linear mixed models, HRV and physical activity indexed by daytime HR (PAiHR) were significantly associated with the ERS/ERC risk parameters. In a logistical mixed model, HRV revealed a significant difference between 1-year mortality ( 5%) (p=0.027) with an OR of 0.82 for being in the group with 1-year mortality >5% for every increase by one HRV unit. Conclusions Risk assessment in PH can be refined with continuous monitoring of HRV and PAiHR. These markers were associated with the ESC/ERC parameters. Our study with continuous risk stratification in PH demonstrated that a lower HRV predict worse prognosis.

Sperm allocation pattern during a reproductive season in the copulating marine cottoid species, Alcichthys alcicornis

Sarcocystis Meningoencephalitis in a Northern Gannet (Morus bassanus)

A claims‐based, machine‐learning algorithm to identify patients with pulmonary arterial hypertension

Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension

Improved Risk Prediction Using a Refined European Guidelines Instrument in Pulmonary Arterial Hypertension Related to Congenital Heart Disease

Risk stratification and medical therapy of pulmonary arterial hypertension

A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines

Abstract 15889: An Artificial Intelligence-Derived Pediatric Pulmonary Hypertension Risk Prediction Model From the Pediatric Pulmonary Hypertension Network (PPHNet) Registry

Identifying consistent echocardiographic thresholds for risk stratification in pulmonary arterial hypertension

Precision phenotyping from routine laboratory parameters for machine learning out-of-hospital survival prediction using 4D time-dependent SHAP plots in an all-comers prospective PCI registry

Identification of metabolic biomarkers in idiopathic pulmonary arterial hypertension using targeted metabolomics and bioinformatics analysis

Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment

Impact of left heart disease risk factors on risk stratification and treatment response in pulmonary arterial hypertension

Risk Assessment in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: CSTAR-PAH Cohort Study.

Cerebral Phaeohyphomycosis in Two Dogs and a Cat

Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype

Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics

Pathologic Quiz Case: An 11-Day-Old Boy With Lethargy, Jaundice, Fever, and Melena

Precision phenotyping from routine laboratory parameters for out of hospital survival prediction in an all comers prospective PCI registry

Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension

Continuous long-term heart rate variability and risk assessment in pulmonary hypertension